Clinical Trial

A Phase II Study of GC101 in NSCLC

Name: A Phase II Study of GC101 in NSCLC — clinical trial record (NCT07560111)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.

Protocol Amendment History 1 change

critical Recruitment opened 2026-08-06

Trial Details

NCT Number	NCT07560111
Lead Sponsor	Shanghai Juncell Therapeutics
Conditions	Non Small Cell Lung Cancer
Enrollment	28 participants
Start Date	2026-06-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-05